Latest stories on ALT
Altimmune price target lowered to $17 from $18 at Evercore ISI
The Fly42 · neutralanalyst
Altimmune to Participate in Stifel Cardiometabolic Forum
Business Insider56 · neutralgeneral
Altimmune’s (ALT) Three Liver Trials Move Forward At Once
Yahoo Finance67 · bullishproduct/pr
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
StockTitan55 · neutralgeneral
Altimmune: Pemvidutide Performs, But A Long Wait Ahead
Seeking Alpha63 · neutralproduct/pr
Altimmune outlines PERFORMA Phase III MASH 52-week data readout expected in 2029 while advancing AUD Phase III planning
Seeking Alpha59 · neutralproduct/pr
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Altimmune Q2 Earnings Call Highlights
Yahoo Finance56 · neutralearnings
Altimmune GAAP EPS of -$0.12 beats by $0.02
Seeking Alpha56 · neutralearnings
Altimmune, Inc. (ALT) files 8-K
SEC 8-K50 · neutralgeneral
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Business Insider59 · neutralproduct/pr
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
GlobeNewswire59 · neutralproduct/pr
Altimmune Q2 2026 Earnings Preview
Seeking Alpha50 · neutralearnings
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Business Insider50 · neutralgeneral
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
StockTitan63 · neutralproduct/pr
ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff
Stocktwits News54 · neutralproduct/pr
Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder - Slideshow
Seeking Alpha59 · neutralproduct/pr
Altimmune Shares Jump Premarket After Positive Results in Phase 2 Trial of Pemvidutide
Morningstar73 · bullishproduct/pr
Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10%
Stocktwits News73 · bullishproduct/pr
Altimmune Shares Jump After Positive Phase 2 Alcohol Use Disorder Trial Results
InvestorsHub73 · bullishproduct/pr
Altimmune Reports Positive Phase 2 Data in AUD
TipRanks67 · bullishproduct/pr
Altimmune rises as GLP-1 cuts drinking in mid-stage trial
Seeking Alpha73 · bullishproduct/pr
Altimmune stock surges 18% on positive trial results
Investing.com Markets73 · bullishproduct/pr
Altimmune, Inc. (ALT) files 8-K
SEC 8-K50 · neutralgeneral
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
StockTitan67 · bullishproduct/pr